Abaloparatide and the Spine: A Narrative Review

References

• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42. doi:10.4158/EP161435.GL
   PubMed Web of Science ®Google Scholar
• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526. doi:10.1002/jbmr.226924771492
   PubMed Web of Science ®Google Scholar
• Wright NC, Saag KG, Dawson-Hughes B, Khosla S, Siris ES. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation. Osteoporos Int. 2017;28(11):3283–3284. doi:10.1007/s00198-017-4207-928936598
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-225182228
   PubMed Web of Science ®Google Scholar
• Lehman RA, Kang DG, Wagner SC. Management of osteoporosis in spine surgery. J Am Acad Orthop Surg. 2015;23(4):253–263. doi:10.5435/JAAOS-D-14-0004225808687
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Hattersley G, Fitzpatrick LA, et al. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2018;29(2):323–328. doi:10.1007/s00198-017-4304-929167971
   PubMed Web of Science ®Google Scholar
• Marrinan S, Pearce MS, Jiang XY, Waters S, Shanshal Y. Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence. Age Ageing. 2015;44(2):258–261. doi:10.1093/ageing/afu12325365963
   PubMed Web of Science ®Google Scholar
• Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN. An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J. 2017;26(3):691–697. doi:10.1007/s00586-015-4342-y26661639
   PubMed Web of Science ®Google Scholar
• Cosman F. The evolving role of anabolic therapy in the treatment of osteoporosis. Curr Opin Rheumatol. 2019;31(4):376–380. doi:10.1097/BOR.000000000000061631090588
   PubMed Web of Science ®Google Scholar
• Ebata S, Takahashi J, Hasegawa T, et al. Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am. 2017;99(5):365–372. doi:10.2106/JBJS.16.0023028244906
   PubMed Web of Science ®Google Scholar
• Hirsch BP, Unnanuntana A, Cunningham ME, Lane JM. The effect of therapies for osteoporosis on spine fusion: a systematic review. Spine J. 2013;13(2):190–199. doi:10.1016/j.spinee.2012.03.03522658879
   PubMed Web of Science ®Google Scholar
• Inoue G, Ueno M, Nakazawa T, et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014;21(3):425–431. doi:10.3171/2014.5.SPINE1365624905394
   PubMed Web of Science ®Google Scholar
• Kaliya-Perumal AK, Lu ML, Luo CA, et al. Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery. Medicine (Baltimore). 2017;96(5):e5996. doi:10.1097/MD.000000000000599628151894
   PubMed Web of Science ®Google Scholar
• Kim JW, Park SW, Kim YB, Ko MJ. The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients. J Korean Neurosurg Soc. 2018;61(4):494–502. doi:10.3340/jkns.2017.021629724093
   PubMed Web of Science ®Google Scholar
• Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23):E1464–8. doi:10.1097/BRS.0b013e31826ca2a822872218
   PubMed Web of Science ®Google Scholar
• Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38(8):E487–92. doi:10.1097/BRS.0b013e31828826dd23354115
   PubMed Web of Science ®Google Scholar
• Ohtori S, Orita S, Yamauchi K, et al. Does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? Asian Spine J. 2017;11(2):272–277. doi:10.4184/asj.2017.11.2.27228443172
   PubMed Web of Science ®Google Scholar
• Ohtori S, Orita S, Yamauchi K, et al. More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J. 2015;9(4):573–580. doi:10.4184/asj.2015.9.4.57326240717
   PubMedGoogle Scholar
• Yagi M, Ohne H, Konomi T, et al. Teriparatide improves volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone failure type PJK after surgery for adult spinal deformity. Osteoporos Int. 2016;27(12):3495–3502. doi:10.1007/s00198-016-3676-627341809
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88(2):569–575. doi:10.1210/jc.2002-02112212574182
   PubMed Web of Science ®Google Scholar
• Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone. 1995;16(4):477–484. doi:10.1016/8756-3282(95)90194-97605709
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol. 2019;166:185–191. doi:10.1016/j.bcp.2019.05.02431136739
   PubMed Web of Science ®Google Scholar
• Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019;76(3):130–135. doi:10.1093/ajhp/zxy02230689744
   PubMed Web of Science ®Google Scholar
• Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res. 2017;32(1):24–33. doi:10.1002/jbmr.300327748532
   PubMed Web of Science ®Google Scholar
• Bernhardsson M, Aspenberg P. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models. Acta Orthop. 2018;89(6):674–677. doi:10.1080/17453674.2018.152377130334479
   PubMed Web of Science ®Google Scholar
• Chandler H, Lanske B, Varela A, et al. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 2019;120:148–155. doi:10.1016/j.bone.2018.10.01230343166
   PubMed Web of Science ®Google Scholar
• Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2018;29(3):685–697. doi:10.1007/s00198-017-4323-629260289
   PubMed Web of Science ®Google Scholar
• Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019;7(19):e14225. doi:10.14814/phy2.1422531565870
   PubMed Web of Science ®Google Scholar
• Leder BZ, O’Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697–706. doi:10.1210/jc.2014-371825393645
   PubMed Web of Science ®Google Scholar
• Hans D, Shevroja E, Lamy O. Use of trabecular bone score as a complementary approach to DXA for fracture risk assessment in clinical practice. Rev Med Suisse. 2017;13(559):844–850.28727341
   PubMedGoogle Scholar
• McCloskey EV, Oden A, Harvey NC, et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res. 2016;31(5):940–948. doi:10.1002/jbmr.273426498132
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Lau E, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE Phase 3 trial. Bone. 2019;120:137–140. doi:10.1016/j.bone.2018.10.01530359763
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733. doi:10.1001/jama.2016.1113627533157
   PubMed Web of Science ®Google Scholar
• McClung MR, Harvey NC, Fitzpatrick LA, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018;25(7):767–771. doi:10.1097/GME.000000000000108029462094
   PubMed Web of Science ®Google Scholar
• Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32(1):17–23. doi:10.1002/jbmr.299127612281
   PubMed Web of Science ®Google Scholar
• Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with teriparatide. Calcif Tissue Int. 2018;103(5):540–545. doi:10.1007/s00223-018-0450-029951742
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–58. doi:10.1016/j.bone.2017.03.00628286299
   PubMed Web of Science ®Google Scholar
• Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957. doi:10.1210/jc.2018-0016329800372
   PubMed Web of Science ®Google Scholar
• Tymlos (R) [Prescirbing Information]. Radius Health, Inc. Waltham, MA; 2018.
   Google Scholar
• Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother. 2019;53(2):134–143. doi:10.1177/106002801879803430160186
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019;49(2):184–196. doi:10.1016/j.semarthrit.2019.01.00630737062
   PubMed Web of Science ®Google Scholar
• Liu Y, Dash A, Krez A, et al. Low volumetric bone density is a risk factor for early complications after spine fusion surgery. Osteoporos Int. 2020;31(4):647–654. doi:10.1007/s00198-019-05245-731919536
   PubMed Web of Science ®Google Scholar
• McCoy S, Tundo F, Chidambaram S, Baaj AA. Clinical considerations for spinal surgery in the osteoporotic patient: a comprehensive review. Clin Neurol Neurosurg. 2019;180:40–47. doi:10.1016/j.clineuro.2019.03.01030921564
   PubMed Web of Science ®Google Scholar
• Kong M, Zhou C, Zhu K, et al. 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women. Clin Interv Aging. 2019;14:1693–1703. doi:10.2147/CIA.S22466331631990
   PubMed Web of Science ®Google Scholar
• Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of abaloparatide versus alendronate on fracture risk reduction in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2019;105(3):938–43.
   Web of Science ®Google Scholar
• Leder BZ, Zapalowski C, Hu MY, et al. Fracture and bone mineral density response by baseline risk in patients treated with abaloparatide followed by alendronate: results from the phase 3 ACTIVExtend trial. J Bone Miner Res. 2019;34(12):2213–2219. doi:10.1002/jbmr.384831411768
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019;14(1):15. doi:10.1007/s11657-019-0564-730719589
   PubMed Web of Science ®Google Scholar